Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Pipeline Monitor
Anticoagulant and blood thinner approved
Approval for anticoagulant, blood thinner while new class of cancer medicine, enzyme replacement therapies and a swag of others bag recommendations.
Working Life
Do appearances matter?
While tattoos and piercings are becoming more mainstream in younger generations, the pharmaceutical industry continues to be very conservative. So, what can you expect for yourself or your staff in regard to appearance?
Special Report
Image problems continue to beset pharma
A spate of mainstream media coverage from tax to medicine prices to trade agreements continues to portray Aussie pharma in a negative light - does the industry have only itself to blame?
Special Report
Big changes proposed at TGA
A wide range of changes have been mooted for the regulator which could speed up approval of medicines and see more information shared post- market, with other regulators and across reimbursement applications.
Pipeline Monitor
BMS ahead in new cancer class
BMS has won the race for new cancer class PD-1 in Europe, where Gardasil 9 has also been approved while Eisai has won a new epileptic indication for Fycompa in the US.